LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. (2020)
Attributed to:
Engineering chimeric antigen receptor T Cells against human LILRB3 for treatment of acute myeloid leukaemia (AML)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1172/jci.insight.141593
PubMed Identifier: 32870822
Publication URI: http://europepmc.org/abstract/MED/32870822
Type: Journal Article/Review
Volume: 5
Parent Publication: JCI insight
Issue: 18
ISSN: 2379-3708